Synthetic aquaretics are vasopressin receptor antagonists, such conivaptan, tolvaptan, demeclocycline and mozavaptan (OPC-31260), as well as lithium. Conivaptan hydrochloride and tolvaptan have been approved by the FDA for treating syndrome of inappropriate antidiuretic hormone (SIADH).